Indian Drug Makers Wary Of Move To Global Customs Standards
This article was originally published in PharmAsia News
Pharmaceutical companies in India are concerned about a government effort to develop global standards for national customs departments. Some pharmaceutical companies fear one proposal under consideration could create a non-tariff situation for their wares in developing countries. The groups say a proposal under consideration for the World Customs Organisation would exceed current minimum standards of global authorities on intellectual property in judging counterfeit goods by having a negative impact on generic versions of drugs. (Click here for more
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.